...For example, if an insider of Genentech realizes that Genentech is likely to win the race ...' stock short may be a close substitute for buying Genentech shares long. . The impetus for substitut...
Euro RSCG Life last year increased revenue by double digits, won a number of major AOR assignments and hired more than 150 people. Worldwide managing partners Donna Murphy and Doug Burcin say these accomplishments stem from a strategy set in motion only a couple of years ago. Steps taken in 2009 involved launching new agencies Catapult and 4D and unifying four flagship units -- including Catapult along with MetaMax, LM&P and Chelsea -- that is, incorporating into each agency all the skill sets needed to drive creative business ideas for clients under one P&L, from advertising, managed markets and DTP to med ed, digital and PR. Another move designed to make it easier for clients to access network assets: Health 4 Brands, which parent Euro RSCG Worldwide debuted overseas last year...
..."Clients aren't buying channels; they're buying ideas to drive their bran... have come from new clients Cephalon, Genentech, Medtronic and Novartis, as well as incremental br...
By Gina Kolata and Andrew Pollack The New York Times
...Looked at one way, Avastin, made by Genentech, is a wonder drug. Approved for patients with adva... requires that the doctor or hospital buying Avastin be paid an amount equal to Genentech's ave...
... new AOR assignments from Cephalon, Genentech, Medtronic and Novartis, and the "unification" of four flagship units. "Clients aren't buying channels," says Worldwide managing partner Donna M...
... sure that I did nothing to jeopardize him buying the conventional business he wanted." ...Ctr. v. Genentech, Inc., 43 Cal. 4th 375, 386 (2008) (quoting Comm. ...
Plaintiffs' lawyers are investigating eye infection outbreaks across the country due to contamination of the drug Avastin. Avastin, which is approved for cancer treatment, is also widely used to treat macular degeneration, although the use is unapproved.
... plaintiffs have filed suit against Genentech, the maker of Avastin, and other defendants, inclu..."They don't want people buying the cheaper product, but they're doing nothing agg...
At the Food and Drug Administration (FDA) these days, the little ladies are to be seen and barely heard. As if "Mad Men" were a documentary rather than a televised slice of 1960s life, a major medical decision looms and the women it affects most directly will be given only a superficial moment to share their substantive views. What do a bunch of gals have to tell the federal government, anyway? Well, a lot, it turns out.
...While wealthy patients will keep buying their Avastin, the FDA's message to those who can'...To its credit, Avastin's manufacturer, Genentech, helps truly needy patients by donating Avastin to...
Mirus Bio Corp. and Roche Holding AG said Tuesday that the giant Swiss pharmaceutical company will acquire the privately-held Madison biotech company for $125 million. The transaction is believed to be the biggest biotech deal announced in Wisconsin so far this year.
...Roche has been on a buying spree, most recently surprising executives of Soutth San Francisco-based Genentech Inc. earlier this week with a $43.7 billion offer ...
... view the post-earnings dip in RIM as a buying opportunity? At what price would the Bull Market R...
... Report newsletter, thinks initial biotech buying interest will be in the larger-cap names with prod...
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2012, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other interesting searches:
Seven Arts Pictures plc | Mark Potter | Airnex Communications, Inc | Whether Stevens | Amisub North Ridge Hospital Inc | Vídeocasete | sabado gigante | costantino vitagliano | Aval cambiario | embajada de italia
